Jefferies analyst Jon Wood published a report on Bruker Corporation BRKR that upgraded its rating from Hold to Buy and raised the price target from $20 to $25.
Jefferies reported that, “Formal 2013 outlook appears more than adequately conservative: While BRKR's business mix (62% gov't / academic / >80% capital equipment) is relatively unfavorable in current environmental conditions, we see improved dynamics in EU gov't / academic endmarkets in 2013 (+4% vs 0% in 2012), which account for 30% of BRKR's revenue (vs 7% for peers). In addition, improved competitive conditions in the NMR / MRI market (33% of revenue), a continuation of elevated new product vitality, and manageable exposure to US gov't / academic markets (10% of revenue) suggest its formal 2013 organic revenue outlook (+3.5% vs +4.0% for peers) is more than adequately conservative in the context of material outperformance historically (+9.0% vs +6.0% for peers).”
Shares of Bruker Corporation closed at $18.68 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in